KAO JOHN E 4

What Happened
John E. Kao, CEO of Alignment Healthcare (ALHC), sold a total of 298,000 shares across three transactions in April 2026 for approximately $6.16 million in aggregate proceeds. The trades were reported on a Form 4 filed 2026-04-13 and consist of:

• 201,900 shares sold on 2026-04-10 — reported weighted-average price $20.58 — proceeds $4,155,243.
• 13,801 shares sold on 2026-04-10 — reported weighted-average price $21.38 — proceeds $295,045.
• 82,299 shares sold on 2026-04-13 — reported weighted-average price $20.80 — proceeds $1,711,655.
  All transactions are recorded as sales (S) — routine dispositions rather than purchases.

Key Details

• Transaction dates: 2026-04-10 (two sales) and 2026-04-13 (one sale). Form 4 filed 2026-04-13 (appears timely).
• Aggregate shares sold: 298,000; aggregate proceeds: ~$6,161,943.
• Reported weighted-average prices and footnote price ranges:
  • 201,900 @ $20.58 (per-share range reported 20.31–21.30).
  • 13,801 @ $21.38 (per-share range reported 21.31–21.49).
  • 82,299 @ $20.80 (per-share range reported 20.26–21.00).
    The filer offers to provide exact per-price breakdowns on request (per filing footnotes).
• 10b5-1 plan: Filing notes a Rule 10b5-1 trading plan adopted 11/21/2025 (footnote). These plans set prearranged trades and are common for scheduled insider sales.
• Ownership after transaction: Not specified in the supplied summary of the filing.
• Trust holdings: Footnote indicates some securities are held by the JEK Trust (dated Feb 8, 2021), for which Mr. Kao is trustee.

Context

• These were straight sales (disposals), not purchases or option exercises. Sales under a 10b5-1 plan are typically pre-scheduled and do not by themselves indicate changed sentiment. Retail investors should view the activity as insider selling but note the 10b5-1 plan disclosure and weighted-average price ranges provided in the filing.